Page 1 | Search Results | Blood | American Society of Hematology

1-14 of 14

Sort by

Sort Order Select

Journal Articles

Importance of Transcription Factor Nrf2 for Cereblon Expression and Clinical Response to Combination of Lenalidomide and Erythropoietin in Lower-Risk Myelodysplastic Syndromes

Radka Bokorová, MSc, Jaroslav Polak, MSc, Anna Jonasova, MD, Radana Neuwirtova, MD PhD, Marie Lauermannova, MD, Jaroslav Cermak, MD PhD, Marketa Stastna, MD PhD, Cyril Salek, Dana Mikulenkova, MD, Zuzana Zemanova, PhD, Jana Brezinova, Kyra Michalova, PhD, Denisa Myslivcova, PhD, Ota Fuchs, PhD

Blood (2018) 132 (Supplement 1): 5507.

https://doi.org/10.1182/blood-2018-99-115803

Published: 2018

Journal Articles

Chromothripsis in High-Risk Myelodysplastic Syndromes: Incidence, Genetic Features, Clinical Implications, and Impact on Survival of Patients Treated with Azacytidine (Data from Czech MDS Group)

Zuzana Zemanova, PhD, Kyra Michalova, PhD, Karla Svobodova, Jana Brezinova, Halka Lhotska, PhD, Libuse Lizcova, PhD, Iveta Sarova, PhD, Silvia Izakova, Lucie Hodanova, PhD, Denisa Vesela, Sarka Ransdorfova, Monika Belickova, PhD, Jitka Vesela, MSc, Helena Polackova, Magda Siskova, MD, Radana Neuwirtova, MD PhD, Jaroslav Cermak, MD PhD, Tomas Stopka, MD PhD, Anna Jonasova, MD

Blood (2018) 132 (Supplement 1): 1815.

https://doi.org/10.1182/blood-2018-99-114151

Published: 2018

Journal Articles

Measurement of Increase in Cereblon mRNA Level after Addition of Erythropoietin to Lenalidomide May Predict a Clinical Response to Combination of Both the Drugs in Patients with Lower-Risk Myelodysplastic Syndromes

Radka Bokorová, Jaroslav Polak, MSc, Arnost Kostecka, Anna Jonasova, MD PhD, Radana Neuwirtova, MD PhD, Tomas Stopka, MD PhD Assoc Proff, Marie Lauermannova, Jaroslav Cermak, MD PhD, Dana Mikulenkova, Zuzana Zemanova, PhD, Jana Brezinova, PhD, Ota Fuchs, PhD

Blood (2017) 130 (Supplement 1): 5295.

https://doi.org/10.1182/blood.V130.Suppl_1.5295.5295

Published: 2017

Journal Articles

Why Patients with 5q- Syndrome Have Thrombocythemia?

Vit Campr, MD PhD, Jan Stritesky, MD PhD, Ota Fuchs, PhD, Anna Jonasova, MD PhD, Zuzana Zemanova, PhD, Radana Neuwirtova, MD PhD

Blood (2016) 128 (22): 5533.

https://doi.org/10.1182/blood.V128.22.5533.5533

Published: 2016

Journal Articles

Frequency and Clinical Impact of Cytogenetic Clonal Evolution in Myelodysplastic Syndromes (MDS) with Isolated Del(5q)

Zuzana Zemanova, PhD, Kyra Michalova, PhD, Jana Brezinova, PhD, Karla Svobodova, Halka Lhotska, Iveta Sarova, PhD, Libuse Lizcova, PhD, Silvia Izakova, Sarka Ransdorfova, PhD, Lenka Pavlistova, PhD, Adela Berkova, PhD, Karolina Skipalova, Monika Belickova, PhD, Magda Siskova, MD, Radana Neuwirtova, MD PhD, Jaroslav Cermak, MD PhD, Tomas Stopka, MD PhD, Anna Jonasova, MD PhD

Blood (2016) 128 (22): 1982.

https://doi.org/10.1182/blood.V128.22.1982.1982

Published: 2016

Journal Articles

The Good Prognosis and Positive Response to the Therapy of Patients with Two Unrelated Clones Del(5q) and Trisomy 8 Does Not Differ to That of the 5q- Syndrome. This Is in Contrast to the Bad Prognosis of Patients with the Same Chromosomal Aberrations in One Clone

Radana Neuwirtova, MD PhD As. Prof., Zuzana Zemanova, Jana Brezinova, PhD, Pavel Dvorak, MD, Ota Fuchs, PhD, Martin Vostry, Anna T Jonasova, MD, Jaroslav Cermak, MD PhD As. Prof., Dana Sponerova, MD, Zuzana Maskova, MD, Libor Cervinek, MD PhD, Vera Vozobulova, MD, Eva Polonyova, MD, Kyra Michalova, PhD Prof.

Blood (2014) 124 (21): 5626.

https://doi.org/10.1182/blood.V124.21.5626.5626

Published: 2014

Journal Articles

Clonal Heterogeneity in Patients with Myelodysplastic Syndromes (MDS) and Complex Karyotypes

Zuzana Zemanova, Ass. Prof.,PhD, Kyra Michalova, PhD Prof., Jana Brezinova, PhD, Halka Lhotska, Karla Svobodova, Iveta Sarova, PhD, Libuse Lizcova, PhD, Silvia Izakova, Sarka Ransdorfova, PhD, Zdenek Krejcik, PhD, Monika Belickova, PhD, Magda Siskova, MD, Anna Jonasova, MD, Radana Neuwirtova, MD PhD As. Prof., Jana Zmolikova, Jaroslav Cermak, MD PhD As. Prof.

Blood (2014) 124 (21): 859.

https://doi.org/10.1182/blood.V124.21.859.859

Published: 2014

Journal Articles

High Cereblon Expression In Lower Risk Myelodysplastic Syndromes With 5q Deletion Is Associated With The Efficacy Of Lenalidomide

Anna T Jonasova, MD, Jaroslav Polak, Martin Vostry, Arnost Kostecka, Radka Bokorova, Radana Neuwirtova, MD, PhD, Magda Siskova, MD, Miroslav Caniga, Dana Sponerova, Jaroslav Cermak, Dana Mikulenková, MD, Jana Brezinova, PhD, Kyra Michalova, PhD, Ota Fuchs, PhD

Blood (2013) 122 (21): 1529.

https://doi.org/10.1182/blood.V122.21.1529.1529

Published: 2013

Journal Articles

Putative Monosomy 5 In Myelodysplastic Syndromes (MDS) Is Probably Resulting From Chromothripsis

Zuzana Zemanova, Kyra Michalova, PhD, Halka Buryova, Jana Brezinova, PhD, Libuse Lizcova, Karla Kostylkova, Iveta Sarova, PhD, Silvia Izakova, Sarka Ransdorfova, Zdenek Krejcik, Michaela Dostalova Merkerova, PhD, Magda Siskova, MD, Anna T Jonasova, MD, Radana Neuwirtova, MD, PhD, Jaroslav Cermak, PhD

Blood (2013) 122 (21): 1559.

https://doi.org/10.1182/blood.V122.21.1559.1559

Published: 2013

Journal Articles

The Significance Of Fli1 and p53 For The Effective Megakaryopoiesis In 5q- Syndrome and The Effect Of Lenalidomide Treatment

Radana Neuwirtova, MD, PhD, Jan Stritesky, MD, PhD, Ota Fuchs, PhD, Martin Vostry, Arnost Kostecka, Monika Belickova, PhD, Magdalena Siskova, MD, PhD, Kyra Michalova, prof., PhD, Jaroslav Cermak, Ass. Prof., PhD, Anna T Jonasova, MD

Blood (2013) 122 (21): 5208.

https://doi.org/10.1182/blood.V122.21.5208.5208

Published: 2013

Journal Articles

The Significance of Megakaryocytic Transcription Factor Fli1 and Erythroid Transcription Factor EKLF in the Ribosomopathies: 5q Minus Syndrome and Diamond-Blackfan Anemia. the Role of Fli1 in p53 Regulation and in 5q Minus Syndrome Megakaryopoiesis,

Radana Neuwirtova, MD, PhD, Ota Fuchs, PhD, Dagmar Pospisilova, MD, PhD, Radek Cmejla, PhD, Monika Holicka, Martin Vostry, Arnost Kostecka, Hana Hajkova, Anna Jonasova, MD, Jaroslav Cermak, MD, PhD, Kyra Michalova, PhD, Jana Brezinova, PhD

Blood (2011) 118 (21): 3825.

https://doi.org/10.1182/blood.V118.21.3825.3825

Published: 2011

Journal Articles

Gene Expression Changes In Patients with 5q- Syndrome Treated with Lenalidomide

Monika Belickova, Jaroslav Cermak, Kamila Fejglova, Michaela Dostalova Merkerova, Radana Neuwirtova, MD, PhD, Miroslav Caniga, Magda Siskova, Libor Cervinek, Anna Jonasova, MD

Blood (2010) 116 (21): 4641.

https://doi.org/10.1182/blood.V116.21.4641.4641

Published: 2010

Journal Articles

Frequency and Prognostic Impact of Complex Chromosomal Aberrations in Patients with Primary Myelodysplastic Syndromes and Del(5q).

Zuzana Zemanova, Ass.Prof., Ph.D., Kyra Michalova, Prof., PhD., Jana Brezinova, Libuse Lizcova, Silvia Izakova, Dagmar Bystricka, PhD, Iveta Sarova, Adela Berkova, MD, Magda Siskova, MD, Radana Neuwirtova, MD, PhD, Olga Cerna, MD, Jaroslav Cermak, M.D., Ph.D.

Blood (2009) 114 (22): 1623.

https://doi.org/10.1182/blood.V114.22.1623.1623

Published: 2009

Journal Articles

Fli-1 and EKLF Gene Expression in Patients with MDS 5q- Syndrome.

Radana Neuwirtova, MD, PhD, Ota Fuchs, V, Dana Provaznikova, Jr., Jaroslav Cermak, V, Magda Siskova, III, Anna Jonasova, V, Kyra Michalova, IV

Blood (2009) 114 (22): 2788.

https://doi.org/10.1182/blood.V114.22.2788.2788

Published: 2009

NARROW

Importance of Transcription Factor Nrf2 for Cereblon Expression and Clinical Response to Combination of Lenalidomide and Erythropoietin in Lower-Risk Myelodysplastic Syndromes

Chromothripsis in High-Risk Myelodysplastic Syndromes: Incidence, Genetic Features, Clinical Implications, and Impact on Survival of Patients Treated with Azacytidine (Data from Czech MDS Group)

Measurement of Increase in Cereblon mRNA Level after Addition of Erythropoietin to Lenalidomide May Predict a Clinical Response to Combination of Both the Drugs in Patients with Lower-Risk Myelodysplastic Syndromes

Why Patients with 5q- Syndrome Have Thrombocythemia?

Frequency and Clinical Impact of Cytogenetic Clonal Evolution in Myelodysplastic Syndromes (MDS) with Isolated Del(5q)

The Good Prognosis and Positive Response to the Therapy of Patients with Two Unrelated Clones Del(5q) and Trisomy 8 Does Not Differ to That of the 5q- Syndrome. This Is in Contrast to the Bad Prognosis of Patients with the Same Chromosomal Aberrations in One Clone

Clonal Heterogeneity in Patients with Myelodysplastic Syndromes (MDS) and Complex Karyotypes

High Cereblon Expression In Lower Risk Myelodysplastic Syndromes With 5q Deletion Is Associated With The Efficacy Of Lenalidomide

Putative Monosomy 5 In Myelodysplastic Syndromes (MDS) Is Probably Resulting From Chromothripsis

The Significance Of Fli1 and p53 For The Effective Megakaryopoiesis In 5q- Syndrome and The Effect Of Lenalidomide Treatment

The Significance of Megakaryocytic Transcription Factor Fli1 and Erythroid Transcription Factor EKLF in the Ribosomopathies: 5q Minus Syndrome and Diamond-Blackfan Anemia. the Role of Fli1 in p53 Regulation and in 5q Minus Syndrome Megakaryopoiesis,

Gene Expression Changes In Patients with 5q- Syndrome Treated with Lenalidomide

Frequency and Prognostic Impact of Complex Chromosomal Aberrations in Patients with Primary Myelodysplastic Syndromes and Del(5q).

Fli-1 and EKLF Gene Expression in Patients with MDS 5q- Syndrome.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only